According to FDA:- “Wegovy’s safety and efficacy were studied in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials (including 16 weeks of dose increases) and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients receiving Wegovy either continued with the treatment or switched to a placebo. More than 2,600 patients received Wegovy for up to 68 weeks in these four studies and more than 1,500 patients received placebo.

The U.S FDA suggests that the largest placebo-controlled trial enrolled adults without diabetes. The average age at the start of the trial was 46 years and 74% of patients were female. The average body weight was 231 pounds (105 kg) and the average BMI was 38 kg/m2. Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received a placebo. Another trial enrolled adults with type 2 diabetes. The average age was 55 years and 51% were female. The average body weight was 220 pounds (100 kg) and the average BMI was 36 kg/m2. In this trial, individuals who received Wegovy lost 6.2% of their initial body weight compared to those who received a placebo.”

The use of Wegovy totally depends on the physician’s prescription, how long the physician feels optimum for you. Usually, The dose of this drug is increased gradually over the period of 16 to 20 weeks to 2.4 mg weekly that reduces the gastrointestinal side effects.

Clinical trials have shown that Wegovy treatment resulted in a statistically significant reduction in body weight compared to placebo after 68 weeks. The trial showed that people taking Wegovy had a mean change in body weight of 14.9% compared to 2.4% in the placebo group.

The results also showed that, after 68 weeks, 83.5% of patients lost 5% or more of their body weight. In the placebo group, 31.1% of patients lost 5% or more of their body weight. Another clinical trial also showed a statistically significant reduction in body weight vs placebo.